Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03472313 · ClinicalTrials.gov registry record · Phase 1
Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects
A Phase 1 study, sponsored by Invicro.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03472313 is a Phase 1 study that has completed, run by Invicro. The registered enrollment target is 2 participants.
The verdict
NCT03472313, a Phase 1 study, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical.
Interventions
- DRUG [18F]MNI-958
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-11-14 |
| Est. Completion | 2018-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03472313
The ClinicalTrials.gov registry entry for NCT03472313 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invicro, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]MNI-958 is the first listed.
NCT03472313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03472313 about?
NCT03472313 is a clinical study titled "Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects". The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical.
What is the current status of trial NCT03472313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2017-11-14. Estimated completion is 2018-04-20.
What interventions are being tested in trial NCT03472313?
The interventions under investigation include: [18F]MNI-958 (DRUG).
Who is sponsoring clinical trial NCT03472313?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.